Biological markers in risk stratification and progression of cardiovascular disease: present and future

Author:

Ostanko V. L.1ORCID,Kalacheva T. P.1ORCID,Kalyuzhina E. V.1ORCID,Livshits I. K.1ORCID,Shalovay A. A.1ORCID,Chernogoryuk G. E.1ORCID,Bespalova I. D.1ORCID,Yunusov R. Sh.2,Lukashova L. V.1ORCID,Pomogaeva A. P.1ORCID,Teplyakov A. T.3ORCID,Kalyuzhin V. V.1ORCID

Affiliation:

1. Siberian State Medical University (SSMU)

2. Medical Сenter “Siberian Doctor”

3. Research Institute Cardiology, Tomsk National Research Medical Center (TNRMC) of Russian Academy of Sciences (RAS)

Abstract

Taking into account the increase in the level of cardiovascular diseases in recent decades, the clinician faces the task of attempting to make the fastest possible diagnosis of the pathology at its earliest stages. That is why the aim of our work was to identify the main groups of biological markers, and to separate the role of each of them in the assessment of the risk of development, progression and possible complications of cardiovascular diseases. We have given the main working classification of markers of cardiovascular processes with the allocation of their main types, as well as the basic criteria for the “ideal” biological marker. Finally, an attempt was made to structure biomarkers depending on their molecular mechanisms of pathogenesis in the development of a particular pathology. All these data should help the clinician at the stage of early diagnosis of cardiovascular disease.

Publisher

Siberian State Medical University

Subject

Molecular Medicine

Reference53 articles.

1. Kalyuzhin V.V., Teplyakov A.T., Solovtsov M.A., Kalyuzhina E.V., Bespalova I.D., Terentyeva N.N. Remodeling of the left ventricle: one or several scenarios? Byulleten’ sibirskoy meditsiny – Bulletin of Siberian Medicine. 2016; 15 (4): 120–139 (in Russ.). DOI: 10.20538/1682-0363-2016-4-120-139.

2. Kalyuzhin V.V., Teplyakov A.T., Kalyuzhin O.V. Heartfailure. Мoscow: Medicinskoe informacionnoe agentstvo Publ., 2018: 376 (in Russ.).

3. Berezin A.E.. Biological markers of cardiovascular disease. Guide for doctors: In 3 parts. Kiev: Morion Publ., 2014. Part 1: 652 (in Russ.).

4. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001; 69 (3): 89–95. DOI: 10.1067/mcp.2001.113989.

5. Colburn W.A. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development. J. Clin. Pharmacol. 2000; 40 (12 Pt. 2): 1419–1427.

Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3